Edition:
United States

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

6,132JPY
8:25pm EST
Change (% chg)

¥-87 (-1.40%)
Prev Close
¥6,219
Open
¥6,195
Day's High
¥6,204
Day's Low
¥6,132
Volume
212,900
Avg. Vol
1,331,571
52-wk High
¥6,465
52-wk Low
¥5,147

Chart for

About

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company. It is engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The Company mainly provides vitamin preparations, analgesic antipyretics, cold and sinus medicine, digestive medicine,... (more)

Overall

Beta: 0.99
Market Cap(Mil.): ¥2,061,380.00
Shares Outstanding(Mil.): 329.14
Dividend: 38.00
Yield (%): 1.15

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Shionogi to repurchase shares and retire treasury shares

* Says it will repurchase up to 4.8 million shares, representing 1.5 percent of outstanding

Nov 27 2017

U.S. FDA approves first two-drug HIV regimen in win for GSK

The U.S. Food and Drug Administration has approved the first two-drug regimen to treat HIV, the virus that causes AIDS, aimed at lessening the side effect burden of current treatments that combine three or four medicines.

Nov 22 2017

UPDATE 2-U.S. FDA approves first two-drug HIV regimen in win for GSK

* Two-drug approach differentiates GSK from Gilead (Adds context on GSK drive to improve pharma sales)

Nov 22 2017

U.S. FDA approves first two-drug HIV regimen

NEW YORK, Nov 21 The U.S. Food and Drug Administration on Tuesday approved the first two-drug regimen to treat HIV, the virus that causes AIDS, aimed at easing the side effects for long-term patients who are on the standard treatment involving three or more drugs.

Nov 21 2017

BRIEF-UMN Pharma says business and capital alliance with Shionogi

* Says it signed business and capital alliance agreement with Shionogi & Co Ltd on Oct. 31

Oct 30 2017

BRIEF-Shionogi and Purdue Pharma announce U.S availability of Symproic (naldemedine)

* Shionogi inc - co, Purdue Pharma L.P. announce that Symproic (naldemedine) 0.2 mg tablets are now available throughout United States​

Oct 12 2017

BRIEF-Shionogi says Lusutrombopag met primary, secondary endpoints in phase 3 study​‍​

* Shionogi & Co Ltd - ‍ Lusutrombopag met primary and all pre-specified important secondary endpoints in a global phase 3 study​

Sep 25 2017

Shire, Shionogi's ADHD drug for adults clears late-stage trial in Japan

TOKYO Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.

Sep 20 2017

Shire, Shionogi's ADHD drug for adults clears late-stage trial in Japan

TOKYO, Sept 20 Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.

Sep 20 2017

BRIEF-Shire and Shionogi announce positive topline results for Intuniv ​

* ‍SHIRE AND SHIONOGI ANNOUNCE POSITIVE TOPLINE RESULTS FOR INTUNIV EVALUATED IN PHASE 3 CLINICAL TRIAL IN ADULTS WITH ADHD​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Sep 20 2017

Earnings vs. Estimates